FOROSI FOROSI FANDIA FANDIA FANDIA AVANDIA AVANDIA NELIZAMET NELIZAMET NELIZAMET NELIZIG NELIZIG NELIZIG ORNIX ORNIX ORNIX RE-CONT ROSITA ROSITA ROSITA ROZIG ROZIG GLANDIA GLANDIA M-RID MR-2 ROSIZONE ESCORT ESCORT ROZIMET ROZIMET ROZIMET ROZIMET PLUS ROZIMET PLUS ROZI ROZI ROZI XETAZONE XETAZONE XETAZONE BLUTAB BLUTAB BLUTAB BLUEMET BLUEMET BLUEMET D-ENGRAX DIAGLIET 3H DIAGLIET 3H ZONA-4 ROSISCOT ROSISCOT GLIZON GLIZON GLIZON ROZA-M ROZICON-M ROZICON-M ROZICON-M ROZICON-M ROZICON-M DIAROZ DIAROZ FORTE ROSISER ROSISER ROSISER ROSISE

Dose: 4 mg
Single Dose: 4 (4)
Frequency: 24 hourly
Route: PO
Instructions: For patients who respond inadequately following 12 weeks of treatment, the dose may be increased to 8 mg administered as single dose or in divided doses twice daily

. It is of Synthetic origin and belongs to Thiazolidinedione. . The Molecular Weight of Rosiglitazone (Maleate) is 473.52. Its pKa is 6.8, 6.1.

Rosiglitazone (Maleate) is contraindicated in conditions like Hypersensitivity,Diabetic ketoacidosis.

The severe or irreversible adverse effects of Rosiglitazone (Maleate), which give rise to further complications include Congestive heart failure, Fluid retension, Oedema, Hypoglycemia, Anaemia, Hypercholesterolemia, Cardiac hypertrophy.The symptomatic adverse reactions produced by Rosiglitazone (Maleate) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Weight gain.

Rosiglitazone (Maleate) is primarily indicated in conditions like NIDDM, Type II diabetes mellitus.

No data regarding the interactions of Rosiglitazone (Maleate) was found.

Hematocrit Value Increases ALT levels

Drug should not be given to Pregnant Mothers.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Tabs Store in a well closed container, . Protect from Sunlight, Moisture and Heat.

It should not be used during pregnancy unless the potential benefits outweighs the potential risk to the fetus. It should not be administered to nursing mothers.